Johns Hopkins University and Deerfield Management will collaborate on a $65 million research initiative to develop early stage therapeutics.
The collaboration, Bluefield Innovations, will over five years support the commercialization of early-stage therapeutic research conducted at Hopkins. Additional funding will be available for research that has a strong commercial potential. Bluefield will focus broadly on therapeutics, including the areas of oncology, neurology and pain.
Deerfield, an investment management firm, will provide the funding.
A joint steering committee will pick Bluefield’s research and guide the development process. That process will include basic research, proof of concept and target selection. It will also include investigational studies to determine candidates to enter into human clinical trials.
Research from Bluefield will be licensed to third parties or spun out as new companies.